
Colleen Kelley, MD, the biggest barriers to HIV prevention methods and how to overcome them.

Colleen Kelley, MD, the biggest barriers to HIV prevention methods and how to overcome them.

Closing treatment gaps is critical to ending the HIV epidemic in the United States.

A new study reveals that the quadrivalent HPV catch-up vaccine was most effective against cancer risk in women who received the first dose between the ages of 14 and 20 years.

Medication advancements offer more options and formulations for treating pediatric patients living with HIV.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

New research from Johns Hopkins reveals that 2 genes, CMPK2 and BCLG, are selectively activated in the presence of type 1 interferon.

Use of ibalizumab in combination with other HIV treatment could be an effective option for adults with advanced drug-resistant HIV.

A phase 3 trial has met its primary endpoint, showing a similar efficacy of a once-a-month injectable 2DR of cabotegravir and rilpivirine compared to daily, oral 3DR.

The method uses genetic sequencing to pinpoint the source of new infections following a community intervention, therefore measuring the impact of the intervention.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

New research shows that incidences of suicidality were higher among patients who were prescribed EFV compared to a control group; the results indicate that EFV, rather that treatment initiation timelines, were correlated with suicidal behavior.

Syphilis continues to spread in indigenous populations residing in 4 jurisdictions throughout Australia.

Better diagnostics and treatment are needed for Mycoplasma genitalium—a lesser-known sexually-transmitted infection estimated to infect up to 3% of the population in many countries.

Science doesn’t support legal punishment of HIV-positive people.

A new CDC analysis underscores the need for HIV testing programs in the southern part of the United States to improve linkage medical care among HIV-positive black men who have sex with men (MSM).

Genital shedding in herpes patients is even more common than genital lesions. Can a new way of testing for the disease streamline the treatment process?

OSA is largely untreated in HIV patients, and this lack of treatment likely contributes to further comorbidity complications associated with the virus.

Eradication of HCV in patients with HIV results in reduction of CD4+ and CD8+ T cell immune activation.

At week 96, 73.1% of patients infected with HIV-1 and treated with once-daily doravirine + other ART medications, achieved viral suppression.

Investigators report results of the first randomized clinical trial to test a novel strategy to wake up and kill dormant HIV hiding in reservoir cells.

Dolutegravir and lamivudine combination regimen met primary endpoint in 2 phase 3 studies of treatment-naïve patients with HIV.

Mosaic-based vaccine regimen maintained humoral and cellular HIV immune responses according to long-term data from APPROACH.

New guidelines on the prevention and treatment of HIV in adults from the IAS-USA Panel highlight advances made since the 2016 guidelines, as well as the need for new strategies.

PARTNER 2 study reports zero HIV transmissions over 8 years in gay couples who did not use condoms and had achieved an undetectable viral load on HIV treatment.

More information continues to come to light on the impact of protease inhibitors on patients with HIV and cardiovascular disease.